1 August 2013Europe

UK Appeals Court upholds Teva’s Copaxone patent

The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Final call: Who are the world’s best in-house counsel?

16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

Europe

Italian medtech startup beats larger US rival in UPC dispute

15 January 2026 Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.

Europe

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

13 January 2026 As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.

More features

Moderna VP and regulatory expert moves to private practice

Crowell adds tech partner with in-house and private practice expertise

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

Pearce IP grows practice with senior patent hire

Sanofi suffers setback in insulin monopoly dispute

Firm adds seven-lawyer team in second major merger

Eli Lilly’s Mounjaro tops list of cyber squatter targets

The quantum advantage: IP considerations for the next generation of life sciences innovation

UK Appeals Court upholds Teva’s Copaxone patent

More on this story

Editor's picks

Editor's picks

More features